UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Wong‐Type Dermatomyositis in an African American Patient

Arthritis & rheumatology (Hoboken, N.J.), 2021-04, Vol.73 (4), p.630-630

2021

Link zum Volltext

Verfügbarkeit prüfen

Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis

Journal of the American Academy of Dermatology, 2018-04, Vol.78 (4), p.769-775.e2

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus

Journal of investigative dermatology, 2021-12, Vol.141 (12), p.2858-2865.e4

2021

Link zum Volltext

Verfügbarkeit prüfen

Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia Mimicking Discoid Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2019-03, Vol.71 (3), p.478-478

2019

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM

Arthritis research & therapy, 2022-03, Vol.24 (1), p.69-69, Article 69

2022

Link zum Volltext

Verfügbarkeit prüfen

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM

Arthritis research & therapy, 2022-01, Vol.24 (1), p.1-12, Article 12

2022

Link zum Volltext

Verfügbarkeit prüfen

Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study

Journal of the American Academy of Dermatology, 2021-04, Vol.84 (4), p.1157-1160

2021

Link zum Volltext

Verfügbarkeit prüfen

A prospective cohort study comparing the performance of interferon gamma release assays in autoimmune skin diseases

Journal of the American Academy of Dermatology, 2022-04, Vol.86 (4), p.948-949

2022

Link zum Volltext

Verfügbarkeit prüfen

Frequency of immunostimulatory herbal supplement use among patients with autoimmune skin disease

Journal of the American Academy of Dermatology, 2022-11, Vol.87 (5), p.1093-1095

2022

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective

Journal of the American Academy of Dermatology, 2021-02, Vol.84 (2), p.572-574

2021

Link zum Volltext

Verfügbarkeit prüfen

The physical and emotional impact of cutaneous dermatomyositis: a qualitative study

Archives of dermatological research, 2023-10, Vol.315 (8), p.2431-2435

2023

Link zum Volltext

Verfügbarkeit prüfen

The effects of immunostimulatory herbal supplements on autoimmune skin diseases

Journal of the American Academy of Dermatology, 2021-04, Vol.84 (4), p.1051-1058

2021

Link zum Volltext

Verfügbarkeit prüfen

Managing interventional clinical trials in the setting of COVID-19: Experience in an autoimmune skin disease unit

JAAD international, 2021-03, Vol.2, p.94-95

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial

Journal of investigative dermatology, 2022-10, Vol.142 (10), p.2651-2659.e1

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus

Journal of the American Academy of Dermatology, 2021-06, Vol.84 (6), p.1562-1567

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Autoimmune Bullous Disorders in Pregnancy

American journal of clinical dermatology, 2018-06, Vol.19 (3), p.391-403

2018

Link zum Volltext

Verfügbarkeit prüfen

The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review

Annals of translational medicine, 2021-03, Vol.9 (5), p.431-431

2021

Link zum Volltext

Verfügbarkeit prüfen

Elephantiasic Pretibial Myxedema: A Rare Manifestation in Graves’ Disease

Journal of Health Science and Medical Research (JHSMR), 2019-05, Vol.37 (2), p.151-155

2019

Link zum Volltext

Verfügbarkeit prüfen

The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.1001-1008

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin: Disease A Randomized Clinical Trial

Journal of investigative dermatology, 2022-04, Vol.142 (10), p.2651-2659.e1

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Cannabinoid type 2 receptor and in vivo efects of LenabasumTM

Arthritis research & therapy, 2022-03, Vol.24 (1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Cannabinoid type 2 receptor and in vivo effects of LenabasumTM

Arthritis research & therapy, 2022-01, Vol.24 (1)

2022

Link zum Volltext

Verfügbarkeit prüfen

AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus

Annals of translational medicine, 2021-03, Vol.9 (5), p.AB004-AB004

2021

Link zum Volltext

Verfügbarkeit prüfen

AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus

Annals of translational medicine, 2021-03, Vol.9 (5), p.AB005-AB005

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(41)

Publikationsform

Sprache

Englisch
(45)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(24)
Dermatology
(17)
Humans
(15)
Dermatomyositis
(10)
Quality Of Life
(6)
Skin Diseases
(6)
Dermatomyositis - Diagnosis
(5)
Lupus
(5)
Middle Aged
(5)
Autoimmune Diseases
(4)
Dermatomyositis - Drug Therapy
(4)
Female
(4)
Male
(4)
Rheumatology
(4)
Skin
(4)
Abstract On Rheumatologic Skin Disease
(3)
Classification
(3)
Clinical Trials
(3)
Dermatomyositis - Pathology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Wong‐Type Dermatomyositis in an African American Patient

Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis

Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus

Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia Mimicking Discoid Lupus Erythematosus

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM

Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study

A prospective cohort study comparing the performance of interferon gamma release assays in autoimmune skin diseases

Frequency of immunostimulatory herbal supplement use among patients with autoimmune skin disease

Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective

The physical and emotional impact of cutaneous dermatomyositis: a qualitative study

The effects of immunostimulatory herbal supplements on autoimmune skin diseases

Managing interventional clinical trials in the setting of COVID-19: Experience in an autoimmune skin disease unit

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial

Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus

Treatment of Autoimmune Bullous Disorders in Pregnancy

Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations

The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review

Elephantiasic Pretibial Myxedema: A Rare Manifestation in Graves’ Disease

The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin: Disease A Randomized Clinical Trial

Correction to: Cannabinoid type 2 receptor and in vivo efects of LenabasumTM

Cannabinoid type 2 receptor and in vivo effects of LenabasumTM

AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus

AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus

Suchergebnisse filtern